Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
申请人:NOSCIRA, S.A.
公开号:EP2281824A1
公开(公告)日:2011-02-09
The present invention is related to a family of furan-imidazolone derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same.
[EN] FURAN-IMIDAZOLONE DERIVATIVES, FOR THE TREATMENT OF COGNITIVE, NEURODEGENERATIVE OR NEURONAL DISEASES OR DISORDERS<br/>[FR] DÉRIVÉS DE FURANE-IMIDAZOLONE POUR LE TRAITEMENT DE MALADIES OU TROUBLES COGNITIFS, NEURODÉGÉNÉRATIFS OU NEURONAUX
申请人:NOSCIRA SA
公开号:WO2011015646A2
公开(公告)日:2011-02-10
The present invention is related to a family of furan-imidazolone derivatives of formula (I), and to their use in the treatment of cognitive, neurodegenerative or neuronal diseases or disorders, such as Alzheimer's disease or Parkinson's Disease. The present invention also relates to pharmaceutical compositions comprising the same.
Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations
PRMT5 is an important protein arginine methyltransferase that catalyzes the symmetric dimethylation of arginine resides on histones or non-histone substrate proteins. It has been thought as a promising target for many diseases, particularly cancer. Despite the potential applications of PRMT5 inhibitors in cancer treatment, very few of PRMT5i have been publicly reported. In this investigation, virtual